SCM
PLRX icon

Stonepine Capital Management’s Pliant Therapeutics PLRX Stock Holding History

Stonepine Capital Management’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$283K Sell
224,650
-5,400
-2% -$6.82K 0.11% 66
2025
Q4 		$281K Sell
230,050
-59,187
-20% -$88.9K 0.2% 55
2025
Q3 		$428K Buy
+289,237
New +$441K 0.35% 44

Other funds holding PLRX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Stonepine Capital Management's PLRX Position: Q1 2026 in Review

Stonepine Capital Management reduced its Pliant Therapeutics (PLRX) stake by 2.3% in Q1 2026, selling an estimated $6.82K and leaving 224,650 shares worth $283K. The position accounts for 0.11% of the portfolio, ranked #66.

Stonepine Capital Management first reported a position in PLRX in Q3 2025 and has held it in 3 quarters since. The position peaked at $428K in Q3 2025. 91 funds tracked by Wall St. Rank hold PLRX as of Q1 2026.

  • Stonepine Capital Management held 224,650 shares of Pliant Therapeutics worth $283K as of Q1 2026.
  • Stonepine Capital Management sold 5,400 Pliant Therapeutics shares in Q1 2026, an estimated $6.82K.
  • Pliant Therapeutics made up 0.11% of Stonepine Capital Management's portfolio in Q1 2026, its #66 holding.
  • Stonepine Capital Management first reported a position in Pliant Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Stonepine Capital Management's Pliant Therapeutics position peaked at $428K in Q3 2025.
  • 91 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q1 2026.

Based on Stonepine Capital Management's 13F filing for Q1 2026, filed 14 May 2026.